major depressive disorder

Generic versions of major depression drug availableMylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Game-changing depression drug on horizon
Game-changing depression drug on horizonFDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide.
Catching and treating MDD in teensAdolescents can benefit from early screening and treatment of major depressive disorder initiated in their pediatrician’s office, according to a new draft recommendation from the US Preventive Services Task Force.
8 high-profile FDA approvalsThere have been 8 high-profile FDA approvals in the last few weeks. Here is an overview.
Rexulti approved for schizophrenia, MDDThe FDA last week approved Rexulti (brexpiprazole) for schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).
New dose of Viibryd approved to treat major depressive disorder in adultsFDA has approved a new dose of vilazodone (Viibryd, Actavis) for the treatment of Major Depressive Disorder (MDD) in adults.
Cognitive therapy added to medications beneficial in some patients with depressionAbout one-third of people with depression derive benefit from adding cognitive therapy to treatment with antidepressant medication, according to a study published in JAMA Psychiatry.
FDA drug approvals: March 2014FDA actions in brief, breakthrough therapy designations, priority review, fast-track designations, orphan drug designations
New SSRI approved in last quarter of 2013FDA approved vortioxetine as oral tablets indicated for the treatment of major depressive disorder.
Drugs in Perspective: Takeda's and Lundbeck’s BrintellixMajor depressive disorder (MDD) is a medical illness that is characterized by depressed mood, hopelessness, and loss of interest.1 According to the National Institute of Mental Health (NIMH), approximately 6.7% of US adult population experienced MDD, with 30.4% of these cases (2.0% of U.S. adult population) classified as severe.